Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

ClinicalTrials.gov ID: NCT00326339

Public ClinicalTrials.gov record NCT00326339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months will be enrolled into the study.

Study identification

NCT ID
NCT00326339
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rigel Pharmaceuticals
Industry
Enrollment
189 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2006
Primary completion
Sep 30, 2007
Completion
Nov 30, 2007
Last update posted
Apr 19, 2009

2006 – 2007

United States locations

U.S. sites
27
U.S. states
16
U.S. cities
25
Facility City State ZIP Site status
Pacific Arthritis Center Medical Group Santa Maria California 93455
DMI research Ocala Florida 34471
Renstar Medical Research Ocala Florida 34471
Arthritis & Osteoporosis Treatment Center Orange Park Florida 32073
Arthritis Associates Inc. Orlando Florida 32804
Arthritis Research of Florida, Inc. Palm Harbor Florida 34684
Arthritis Research of Florida Palm Harbor Florida 34684
Lovelace Scientific Resources Sarasota Florida 34233
The Center for Arthritis and Rheumatic Diseas South Miami Florida 33143
Coeur d'Alene Arthritis Clinical Trials Coeur d'Alene Idaho 83814-2644
The Arthritis Center Springfield Illinois 62704
MMG Clinical Research South Bend Indiana 46601
Phase III Clinical Research Fall River Massachusetts 02720
Michigan Arthritis Research Center Brighton Michigan 48116
Westroad Medical Group Omaha Nebraska 68114
NC Arthritis & Allergy Care Center Raleigh North Carolina 27609
Clinical Research Division Mayfield Village Ohio 44143
Lynn Health Science Institute Oklahoma City Oklahoma 73112
East Penn Rheumatology Associates Bethlehem Pennsylvania 18015
Altoona Ctr. for Clinical Research Duncansville Pennsylvania 16635
Clinical Research Center of Reading LLP West Reading Pennsylvania 19611
Low Country Rheumatology Charleston South Carolina 29406
Arthritis Clinic Jackson Tennessee 38305
SCRI Memphis Tennessee 38115
Austin Rheumatology Research Austin Texas 78705
Research Across America El Paso Texas 79902
Center for Arth. & Rheum. Disease, PC Chesapeake Virginia 23320

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00326339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2009 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00326339 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →